AZD5863

AZD5863 is a bispecific antibody developed by AstraZeneca. Its targets are Claudin 18.2 and CD3 (the sponsor names CLDN18.2 x CD3). The sponsor states: T cell-engaging bispecific antibody that binds Claudin 18.2 on tumour cells and CD3 on T cells, bridging them to drive immune-mediated tumour cell killing. ClinicalTrials.gov describes the intervention as: T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumour cells and CD3 on T cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and oesophageal cancer. The largest, NCT06005493, plans to enrol 280 participants with primary completion expected 2027-07-16. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.